A first-in-human, open-label, phase I trial of daily oral zelenirstat, an NMT inhibitor, in patients with relapsed/refractory advanced cancer including gastrointestinal cancers.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p129-129, 235p
- Subject
- Language
- ISSN
- 0732183X